Pharmacokinetics of OPB-2045 in Rats : Systemic Exposure following Oral, Subcutaneous, and Intravenous Administration

スポンサーリンク

概要

• 論文の詳細を見る
• 1998-08-28

著者

• Odomi Masaaki

  大塚製薬株式会社徳島研究所

• KUDO Shoji

  大塚製薬株式会社徳島研究所

• UMEHARA Ken

  大塚製薬株式会杜徳島研究所

• MIYAMOTO Gohachiro

  大塚製薬株式会杜徳島研究所

• Miyamoto G

  Otsuka Pharmaceutical Co. Ltd. Tokushima

関連論文

• Absorption and Excretion of OPB-2045 following a Single Oral Administration to Rats
• Absorption, Distribution and Excretion of OPB-2045 following a Single Subcutaneous Administration to Beagle Dogs
• Absorption, Distribution and Excretion of OPB-2045 following a Single Subcutaneous Administration to Rats
• Percutaneous Absorption and Tissue Distribution of 1- (3, 4-dichlorobenzyl) -5-octylbiguanide (OPB-2045) in Rats
• Distribution (Autoradiography) of a New Synthetic Antibacterial Agent OPB-2045 in Rats
• Leukopenia-Inducing Effect of a Combination of a New 5-Fluorouracil (5-FU)-Derived Drug, BOF-A2(Emitefur), with Other 5-FU-Derived Drugs or BV-araU(Sorivudine) in Rats
• Metabolism of a New Bactericidal Antiseptic, OPB-2045, in Rats following Subcutaneous Administration
• Pharmacokinetics of OPB-2045 in Rats : Systemic Exposure following Oral, Subcutaneous, and Intravenous Administration
• Metabolism of a New 1,4-dihydropyridine Calcium Antagonist, Pranidipine, by cDNA-expressed Human Cytochrome P450

スポンサーリンク